InnoCare IPO tackles virus with virtual roadshow
Global equity capital markets suffered severe hits this week, as governments scrambled to respond to an escalation in the coronavirus pandemic. But amid the mayhem, InnoCare Pharma saw an opportunity to launch its IPO, treating Hong Kong to its largest listing in about two months. Jonathan Breen reports.
InnoCare, a Chinese biopharmaceuticals company, is aiming to raise up to HK$2.24bn ($288m) from an all-primary share offering.The flotation comes as equity deals across the world are being delayed because of travel bans and avoidance of face-to-face meetings. But InnoCare is tackling this hurdle in a relatively ...
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: email@example.com